MARK4 regulates NLRP3 positioning and inflammasome activation through a microtubule-dependent mechanism

Xuan Li¹, Sarah Thome¹, Xiaodan Ma², Mamta Amrute-Nayak³, Alison Finigan¹, Lauren Kitt¹, Leanne Masters¹, John R. James⁴, Yuguang Shi⁵, Guoyu Meng² & Ziad Mallat¹,⁶

Excessive activation of the NLR family pyrin domain containing 3 (NLRP3) inflammasome is involved in many chronic inflammatory diseases, including cardiovascular and Alzheimer’s disease. Here we show that microtubule-affinity regulating kinase 4 (MARK4) binds to NLRP3 and drives it to the microtubule-organizing centre, enabling the formation of one large inflammasome speck complex within a single cell. MARK4 knockdown or knockout, or disruption of MARK4-NLRP3 interaction, impairs NLRP3 spatial arrangement and limits inflammasome activation. Our results demonstrate how an evolutionarily conserved protein involved in the regulation of microtubule dynamics orchestrates NLRP3 inflammasome activation by controlling its transport to optimal activation sites, and identify a targetable function for MARK4 in the control of innate immunity.
Inflammasomes are important signalling platforms of the innate immune system, poised to detect a wide range of molecular signatures including pathogens and sterile agents. They are multiprotein complexes with a key component consisting of a NOD-like receptor (NLR) family member or Pyrin and HIN domain-containing protein (PYHIN) family member, connected to caspase-1 mostly through an adaptor protein named apoptosis-associated Speck-like protein with a caspase-recruitment domain (ASC, encoded by PyCARD). Activation of inflammasome pathways triggers caspase-1-dependent processing of immature interleukin 1β (pro-IL-1β) into bioactive IL-1β. Activation of NLRP3, an NLR member of the inflammasome family, is linked to the pathogenesis of various disorders. A better understanding of the regulation of NLRP3 inflammasome activation is therefore required for the development of effective therapies to combat a range of inflammatory diseases.

Microtubule-dependent sorting is critical for the subcellular localization of many organelles, vesicles, macromolecules and pathogens. Studies indicate that microtubules regulate intracellular sorting of NLRP3 (refs 5,6), microtubule-mediated assembly of the NLRP3 inflammasome, and microtubule disruption attenuates NLRP3 inflammasome activation. Data indicate that the centrosomal protein NEK7 is important in the regulation of NLRP3 activity, but inhibition of tubulin polymerization does not affect the NLRP3-NEK7 interaction. Thus, the molecular mechanisms through which NLRP3 is sorted in a microtubule-dependent manner, and the functional consequences of these processes, are not well understood.

The microtubule-affinity regulating kinase 4 (MARK4) protein was discovered by its ability to phosphorylate microtubule-associated proteins (MAP) and thereby regulates microtubule dynamics. The cellular functions of MARK4 have mostly been investigated in neurons, but MARK4 has versatile functions that extend beyond the regulation of microtubule dynamics to a variety of cellular processes including cell polarity, organelle positioning, intracellular transport, signal transduction, ciliogenesis and adipogenesis.

In this study, we identify a functional requirement of MARK4 in the sorting and activation of the NLRP3 inflammasome. Our results show that delivery of NLRP3 through a MARK4-regulated machinery to the correct position on microtubule-organizing center (MTOC) is also very important in determining NLRP3 activation. We demonstrate that amongst the various NLR members of inflammasome family, MARK4 selectively interacts with NLRP3 and promotes its recruitment to mitochondria. Remarkably, we show that MARK4 drives NLRP3 to MTOC, thereby allowing NLRP3 positioning to the characteristic speck structure in a microtubule-dependent manner, and providing an explanation for the presence of only one inflammasome complex per cell. Furthermore, loss of MARK4 or disruption of the interaction between NLRP3 and MARK4, alters NLRP3 inflammasome activation. Finally, we show that loss of MARK4 reduces neutrophil recruitment upon monosodium urate (MSU)-induced inflammasome activation in vivo. Collectively, these data highlight a requirement of MARK4 in facilitating microtubule-based transport of NLRP3, and identify a functional interaction that regulates NLRP3 positioning and optimal activation output. The identification of MARK4 as a NLRP3 binding partner advances our understanding of the molecular mechanisms contributing to inflammasome sorting by microtubule-based transport, and identifies a potential therapeutic target.

**Results**

**Loss of MARK4 alters NLRP3-dependent IL-1β production.** Microtubule-depolymerizing agent colchicine is an effective medicine to treat the acute phase of gout inflammatory disease. Recent studies indicate that microtubule-driven spatial arrangement of mitochondria promotes activation of NLRP3 inflammasome. Moreover, colchicine blocks IL-1β production in response to MSU. To confirm the requirement of microtubules in regulating IL-1β production, we showed that in C57BL/6 mouse bone marrow derived macrophages (BMDM), microtubule-disrupting drugs including colchicine, nocodazole, and vinblastine suppressed IL-1β production in response to the NLRP3 inflammasome stimulus ATP (Supplementary Fig. 1). We therefore addressed in detail how microtubule-related functions are linked to the regulation of NLRP3 inflammasome activation. MARK4 is upregulated during permanent focal cerebral ischemia and in brain tissue during Alzheimer’s disease, indicating a potential regulatory role in the context of sterile inflammation. MARK4 null mice are protected from diet-induced obesity and insulin resistance, a very similar phenotype to Nlrp3 null mice. In situ proximity ligation assay (PLA) is suitable for quantitative studies of protein expression, protein modifications and close protein interactions. By using this assay, we found that MARK4 was endogenously expressed in macrophages, including mouse BMDM (Fig. 1a and Supplementary Fig. 2c) and differentiated human THP-1 cells (Supplementary Fig. 2a,b). The expression level of Mark4 was inducible by LPS priming (Fig. 1a and Supplementary Fig. 2c). Under a wide set of NLRP3 stimuli, including ATP, nigericin, or sterile crystals, knock down of MARK4 using small interfering RNAs (siRNA) or short hairpin RNA (shRNA; Supplementary Fig. 2d) significantly reduced IL-1β production (Fig. 1b,c). We further delineated the specificity of Mark4 by demonstrating that Mark4 knock-out (indicated as Mark4 KO or Mark4/−/−) BMDMs had reduced level of IL-1β production specifically after activation by NLRP3 stimuli when compared with wild-type cells (indicated as WT or Mark4+/+), but not after incubation with stimuli (for example, flagellin, dA:dT, muramyl dipeptide or iE-DAP) known to induce other inflammasome pathways (Fig. 1d). Upon NLRP3 activation, IL-1β production by Mark4 KO cells was not totally ablated as compared with Nlrp3 KO cells, indicating a regulatory role of MARK4 in optimizing NLRP3 activation, or a partial compensatory/redundant mechanism occurring in Mark4/−/− BMDMs. Importantly, IL-1β reduction in Mark4/−/− cells was not caused by the following: altered levels of Nlrp3 (Fig. 1e; Supplementary Fig. 3a,b), pro-caspase-1 or pro-IL-1β substrates (Supplementary Fig. 3); perturbed macrophage differentiation (Supplementary Fig. 4); compromised phagocytosis of crystals (Supplementary Fig. 5); or reduced macrophage viability (Supplementary Fig. 6d,e). Reduced IL-1β levels in Mark4−/− BMDM cells after activation of NLRP3 were due to reduced generation of active caspase-1 and active IL-1β (Fig. 1e).

Surprisingly, we did not see any difference in cell death rate between WT and Mark4 KO cells upon NLRP3 inflammasome activation (Supplementary Fig. 6d,e). Inhibition of inflammasome-dependent caspase-1 activation and IL-1β is not always associated with reduction of cell death. In the case of Mark4 deficiency, this could be due to residual caspase-1 cleavage, altered cell death kinetics, or existence of alternative cell death control in Mark4 KO cells. In addition, inflammasome pathway-independent TNF production was comparable between wild-type and knock-out cells under different treatment conditions (Supplementary Fig. 6a). These results indicate a specific role of Mark4 in Nlrp3 inflammasome activation.

MARK4 is primarily associated with NLRP3 inflammasome. NLRP3 inflammasome complex include NLRP3 itself, ASC adaptor, and caspase-1 (ref. 23). By using PLA to detect protein-protein interaction in situ, we found that Mark4 (or MARK4) was
Figure 1 | Loss of MARK4 affects IL-1β production under NLRP3 inflammasome activation. (a) Mark4 expression under unprimed and LPS primed conditions in mouse bone marrow-derived macrophages (BMDM). Cytoplasm proximity ligation assay (PLA) signal per cell cytoplasm is used for quantification. Mean ± s.e.m. for all the cells taken from 5 to 8 different views at × 40 magnification for each group. Experiments have been repeated three times. Scale bar, 10 µm. (b) siRNA of MARK4, NLRP3 or ASC caused reduction of ATP induced IL-1β production in THP-1 cells. (c) shRNA of MARK4 caused reduction of IL-1β induced by NLRP3 stimuli, including monosodium urate (MSU) and cholesterol crystals (CC) in THP-1 cells. Mock represents macrophages without further stimulation. (d) BMDM derived from Mark4 KO mice exhibited selectivity towards NLRP3 activating stimuli. Mean ± s.e.m., three to four independent experiments combined (b–d), comparisons of the two different groups were analysed by unpaired t test. NS was considered as not statistically significant. *P<0.05, **P<0.01 and ***P<0.001 were considered as statistically significant (a–d). (e) Representative western blots of caspase-1 (Casp1) and IL-1β in the supernatant (Sup.) in Mark4+/+ and Mark4−/− macrophages activated with indicated stimuli. Cell lysates were used as controls to indicate equal amount of cells for analysis.
We were also not able to detect any association between MARK4 and other inflammasomes (NLRP1, NLRC4, or Aim2; Supplementary Fig. 7b), which is in line with the lack of any impact of Mark4 deficiency on IL-1β production in response to stimuli targeting those inflammasome pathways (Fig. 1d). Furthermore, mammalian MARK family has 4 members, and NLRP3 was specifically and highly-associated with MARK4 but not with other members of the MARK family (Supplementary Fig. 7c), supporting a specific role of MARK4 in this pathway. Collectively, those data demonstrate a genuine, primary and specific interaction between MARK4 and NLRP3.

MARK4 has a conserved structure consisting of four distinct domains, including a kinase and a catalytic domain25,26. NLRP3 is composed of a C-terminal leucine-rich repeat domain for sensing the ligands, a central nucleotide-binding domain for oligomerization, and an N-terminal effector pyrin domain (PYD)23. The PYD domain of NLRP3 is important for promoting ASC assembly by binding to GBP5 (ref. 22), and controls positioning of NLRP3 to mitochondria by binding to MAVS27. To understand the molecular mechanism of NLRP3/MARK4 association, we mapped the interaction between NLRP3 and MARK4 using various truncations of these two proteins. We found that MARK4 catalytic kinase

**Figure 2 | MARK4 interacts with NLRP3 in a microtubule-dependent manner.** (a) Upon nigericin stimulation (3 μM for 2 h), microtubule-disrupting drugs colchicine and nocodazole reduced the interaction between Mark4 and Nlrp3, shown by PLA signals in WT BMDM cells. Mark4 KO and Nlrp3 KO BMDM cells were employed as controls. (b) MARK4 was associated with NLRP3 in co-immunoprecipitation assay. Whole cell lysates were analysed as indication of transfection. Western blots are representative of 3 independent experiments. (c) Upon nigericin stimulation, PLA signal of Nlrp3 and Mark4, or Asc and Mark4 in BMDM cells derived from WT or Nlrp3 KO. Secondary only was employed as control in this PLA assay. (d) PLA signal of Nlrp3 and Asc in BMDM cells derived from WT or Nlrp3 KO or Asc KO before or after nigericin stimulation (3 μM for 2 h). Mean ± s.e.m. for all the cells taken from 5 to 8 different views at × 40 magnification for each group (a,b,d). Comparisons of the two different groups were analysed by unpaired t-test. NS was considered as not statistically significant. *P<0.05, **P<0.001 and ****P<0.0001 were considered as statistically significant (a,c,d). Results are representatives of three independent experiments. Scale bar, 10 μm.
domain and NLRP3 Pyrin-NACHT domains were essential for this interaction (Fig. 3a–c). We therefore mutated to Glycine (G) amino acids of this PYD region (L41, R43, V52, and L54) predicted to bind to MARK4. Interestingly V52G displayed a substantial reduction of binding affinity to MARK4 (Fig. 3d), suggesting an essential role of this region of NLRP3 in binding to MARK4. Furthermore, we demonstrated that purified recombinant MARK4 protein was able to bind to immobilized recombinant NLRP3 (1–219 amino acids (aa)) using GST pull-down assay (Fig. 3e), indicating a direct binding between these two proteins.

**MARK4 is involved in NLRP3 positioning along microtubules.**

A role for mitochondria in assembly of NLRP3 inflammasome has been demonstrated, but we have very little understanding of how NLRP3 is mobilized from the cytosol to the mitochondria. A well-known function of MARK4 Drosophila homologue partitioning defective gene 1 (Par-1) is to position macromolecules like STAUFEN protein and oskar mRNA to the correct destination in a microtubule-dependent manner. However, the mechanism through which Par-1 delivers such function is still not fully understood. We directly observed the transport of NLRP3 along microtubules in living cells. We found that stimuli causing NLRP3 inflammasome activation like nigericin, acting as polarizing inputs, induced dynamic NLRP3 transport along microtubules to meet mitochondria (Fig. 4a; Supplementary Movie 1). NLRP3 particles were able to move for a long distance (up to 12.7 μm) with a high speed (up to 577 nm s~1~), and displayed both uni-directional and bidirectional movements.

---

**Figure 3 | Mapping of interacting domains between MARK4 and NLRP3.** (a) Western blots of co-immunoprecipitated full-length NLRP3 with truncated MARK4 (KD: kinase domain; CD: catalytic domain; UBA: Ubiquitin-associated domain), respectively. (b) Western blots of coimmunoprecipitated truncated NLRP3 (Pyrin Del: pyrin domain deletion; Pyrin only: pyrin domain only; NACHT: Nucleotide-binding oligomerization domain; LRR: Leucine-rich repeat) with full-length MARK4, or co-immunoprecipitated MARK4 with truncated NLRP3, respectively. (c) Schematic diagram showing that MARK4 catalytic kinase domain and NLRP3 Pyrin &NACHT domain were essential for their interaction. (d) Western blots of co-immunoprecipitated NLRP3 point mutants with MARK4 respectively. Whole cell lysates were analysed as indication of transfection. (e) Purified recombinant NLRP3 (1-291aa) immobilized on the glutathione sepharose can pull down purified recombinant full-length MARK4 directly. Western blots are representatives of three independent experiments.
bi-directional motor-dependent movements (Supplementary Fig. 9a; Supplementary Movie 2), further supporting a microtubule-dependent transport of NLRP3. In addition, we further confirmed that shuttling of NLRP3 protein to the mitochondria was substantially reduced in MARK4 knock-down macrophages (Fig. 4b; Supplementary Movie 3; Supplementary Fig. 10), supporting a direct role for MARK4 in the transport of NLRP3 from other compartments to mitochondria. Interestingly, there was no apparent difference of run length and run speed of mobile NLRP3 particles in MARK4 knock-down cells when compared with controls (Supplementary Fig. 9b; Supplementary Movie 2), indicating that the positioning defect was not due to a delayed transport process in the absence of MARK4. Together, our results strongly support an evolutionarily conserved role of MARK4 in microtubule-dependent transport.

**MARK4 drives NLRP3 to MTOC upon in&am;lashmasome activation.** MARKs were originally identified through their ability to regulate microtubule stability by phosphorylating and dissociating
the formation of one big condensed speck structure in the cell following its activation, and support an evolutionarily conserved role of MARK in the organization of microtubules and in arranging the distribution of their binding partners.

**Disruption of MARK4-NLRP3 interaction alters speck formation.** We found that a region present in NLRP3 PYD domain, displayed high structural similarity with a known structure of CagA (Supplementary Fig. 14a, b), a peptide originally derived from Helicobacter pylori and subsequently shown to mimic the substrates of MARK proteins. According to the structural alignment between NLRP3 PYD and CagA peptide, we hypothesized that CagA peptide may be employed as a NLRP3 binding competitor against MARK4 to disrupt MARK4-NLRP3 interaction. A control peptide was designed by mutating the predicted binding sites to glycine (Supplementary Fig. 14c). Indeed, incubation with CagA peptide before NLRP3 stimulation with nigericin abrogated the interaction between NLRP3 and MARK4 in THP-1 cells (Fig. 6a), confirming our hypothesis. Moreover, treatment with CagA peptide led to a dose-dependent reduction of caspase-1 activation and IL-1β production in WT BMDMs (Fig. 6b; Supplementary Fig. 14d). CagA peptide did not alter inflammasome-induced IL-1β production in MARK4 deficient cells (Fig. 6b), indicating a MARK4-dependent effect of this peptide. The results strongly support the use of CagA peptide as a potent and selective inhibitor of NLRP3 inflammasome pathway. Inhibition of MARK4/NLRP3 interaction, by CagA treatment or using MARK4 KO, also reduced the interaction between Nlrp3 and Asc (Fig. 6c), demonstrating an important role of MARK4/NLRP3 interaction in the assembly of an optimal inflammasome complex. Moreover, CagA peptide prevented NLRP3 from forming a speck on MTOC (Fig. 6d). The overlapping of MTOC with NLRP3 speck structure was significantly reduced by treatment with CagA peptide (Fig. 6d). Our data collectively highlight an essential role of MARK4 in generating an optimal level of NLRP3 inflammasome activation.

**MARK4 promotes NLRP3-dependent responses in vivo.** MSU crystals accumulate in gout disease and trigger NLRP3-dependent innate immune system activation leading to the release of IL-1β, which is responsible for the neutrophilic gouty inflammation. To assess the contribution of MARK4 to NLRP3 activation in vivo, we used a well-validated NLRP3-dependent acute sterile inflammatory model in mice, induced by the injection of MSU into the peritoneal cavity. As expected, we detected a pronounced influx of neutrophils (Ly6C hi Ly6C + cells) into the peritoneum of wild-type mice after MSU injection (Fig. 6d), which was largely dependent on NLRP3 activation and IL-1β production (Fig. 6c) because it was substantially reduced in Nlrp3−/− mice or after administration of a neutralizing anti-IL-1β antibody (Fig. 7b,c). Interestingly, IL-1β production and neutrophil accumulation in peritoneal lavage were markedly reduced after MSU injection into MARK4−/− mice compared with wild-type mice after treatment with IL-1β neutralizing antibody (Fig. 7b,c). The overlapping of MTOC with NLRP3 speck structure was significantly reduced by treatment with CagA peptide (Fig. 6d). Our data collectively highlight an essential role of MARK4 in generating an optimal level of NLRP3 inflammasome activation.

**MARK4 promotes NLRP3-dependent responses in vivo.** MSU crystals accumulate in gout disease and trigger NLRP3-dependent innate immune system activation leading to the release of IL-1β, which is responsible for the neutrophilic gouty inflammation. To assess the contribution of MARK4 to NLRP3 activation in vivo, we used a well-validated NLRP3-dependent acute sterile inflammatory model in mice, induced by the injection of MSU into the peritoneal cavity. As expected, we detected a pronounced influx of neutrophils (Ly6C hi Ly6C + cells) into the peritoneum of wild-type mice after MSU injection (Fig. 6d), which was largely dependent on NLRP3 activation and IL-1β production (Fig. 6c) because it was substantially reduced in Nlrp3−/− mice or after administration of a neutralizing anti-IL-1β antibody (Fig. 7b,c). Interestingly, IL-1β production and neutrophil accumulation in peritoneal lavage were markedly reduced after MSU injection into MARK4−/− mice compared with wild-type mice after treatment with IL-1β neutralizing antibody (Fig. 7b,c). The overlapping of MTOC with NLRP3 speck structure was significantly reduced by treatment with CagA peptide (Fig. 6d). Our data collectively highlight an essential role of MARK4 in generating an optimal level of NLRP3 inflammasome activation.

**MARK4 promotes NLRP3-dependent responses in vivo.** MSU crystals accumulate in gout disease and trigger NLRP3-dependent innate immune system activation leading to the release of IL-1β, which is responsible for the neutrophilic gouty inflammation. To assess the contribution of MARK4 to NLRP3 activation in vivo, we used a well-validated NLRP3-dependent acute sterile inflammatory model in mice, induced by the injection of MSU into the peritoneal cavity. As expected, we detected a pronounced influx of neutrophils (Ly6C hi Ly6C + cells) into the peritoneum of wild-type mice after MSU injection (Fig. 6d), which was largely dependent on NLRP3 activation and IL-1β production (Fig. 6c) because it was substantially reduced in Nlrp3−/− mice or after administration of a neutralizing anti-IL-1β antibody (Fig. 7b,c). Interestingly, IL-1β production and neutrophil accumulation in peritoneal lavage were markedly reduced after MSU injection into MARK4−/− mice compared with wild-type mice after treatment with IL-1β neutralizing antibody (Fig. 7b,c). The overlapping of MTOC with NLRP3 speck structure was significantly reduced by treatment with CagA peptide (Fig. 6d). Our data collectively highlight an essential role of MARK4 in generating an optimal level of NLRP3 inflammasome activation.

**MARK4 promotes NLRP3-dependent responses in vivo.** MSU crystals accumulate in gout disease and trigger NLRP3-dependent innate immune system activation leading to the release of IL-1β, which is responsible for the neutrophilic gouty inflammation. To assess the contribution of MARK4 to NLRP3 activation in vivo, we used a well-validated NLRP3-dependent acute sterile inflammatory model in mice, induced by the injection of MSU into the peritoneal cavity. As expected, we detected a pronounced influx of neutrophils (Ly6C hi Ly6C + cells) into the peritoneum of wild-type mice after MSU injection (Fig. 6d), which was largely dependent on NLRP3 activation and IL-1β production (Fig. 6c) because it was substantially reduced in Nlrp3−/− mice or after administration of a neutralizing anti-IL-1β antibody (Fig. 7b,c). Interestingly, IL-1β production and neutrophil accumulation in peritoneal lavage were markedly reduced after MSU injection into MARK4−/− mice compared with wild-type mice after treatment with IL-1β neutralizing antibody (Fig. 7b,c). The overlapping of MTOC with NLRP3 speck structure was significantly reduced by treatment with CagA peptide (Fig. 6d). Our data collectively highlight an essential role of MARK4 in generating an optimal level of NLRP3 inflammasome activation.
Discussion

The importance of microtubules in the response of macrophages to inflammatory stimuli has been suggested in very early studies, and recent work has linked microtubule function with inflammasome activity. However, the molecular mechanisms behind this function remained largely unknown. Here we identify MARK4 as a specific immune modulator of NLRP3 inflammasome. We have made several observations that point to MARK4 as a specific player in NLRP3 inflammasome pathway. First, MARK4 specifically regulates NLRP3 inflammasome but does not affect several other inflammasome pathways examined, which is rendered possibly by a unique interaction between NLRP3 and MARK4 proteins. Secondly, other MARK family members (MARK1, MARK2 and MARK3) show very limited binding ability to NLRP3, supporting a distinct role of MARK4 in this pathway. Thirdly, MARK4 regulates NLRP3 inflammasome activation by specifically targeting a fraction of NLRP3. This fraction of NLRP3 requires MARK4 for its shuttling to sites of optimal activation. Therefore, inflammasome activation is significantly reduced but not completely abolished in MARK4 knock-out cells upon both crystalline and non-crystalline activators, which may preserve a homeostatic inflammatory response. In this regard, it is interesting to note that loss of MAVS, a mitochondria protein required for assembly of inflammasome complex on this organelle, also results in a partial repression of inflammasome activation in response to non-crystalline activators, and does not alter NLRP3 inflammasome activation by non-crystalline activators. Thus, it is plausible that different molecules like MARK4 and MAVS are allocated different but complementary tasks during the process of inflammasome activation, and that such division of labour may ensure optimal regulation of NLRP3 positioning and activation in response to polarizing cues. This hypothesis merits further investigation.
Figure 6 | CagA impairs inflammasome activation by disrupting NLRP3-MARK4 interaction. (a) CagA peptide impaired the interaction between NLRP3 and MARK4 upon NLRP3 inflammasome activation by nigericin (3 μM for 2 h) in the differentiated THP-1 cells. A control peptide was employed. Scale bar, 10 μm. (b) ELISA of IL-1β level in the supernatants of WT BMDM cells following pretreatment of CagA peptide (with indicated concentrations) and nigericin stimulation (10 μM for 1 h). Mark4 KO cells were used as controls. (c) CagA peptide prevented formation of Nlrp3 and Asc complex under nigericin stimulation (3 μM for 2 h) in WT BMDMs. Mark4 KO cells were used as controls. Scale bar, 10 μm. Mean ± s.e.m. for all the cells taken from five different views at × 40 magnification for each group (a,c). (d) CagA peptide impaired the formation of NLRP3 speck on MTOC upon NLRP3 inflammasome activation (MSU 250 μg ml⁻¹ for 6 h) in the differentiated THP-1 cells. Inset was used to display magnification of the boxed region as examples of MARK4, NLRP3, and γ-tubulin localization. Scale bar, 20 μm. Mean ± s.e.m., at least three experiments (a–d). Comparisons of the two different groups were analysed by unpaired t test. NS was considered as not statistically significant. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 were considered as statistically significant (a–d).
NLRP3 and epithelia15,29,42. There is a network of cross-regulatory and NLRP3 activation6. However, we did not detect any alteration of apparatus. Microtubule acetylation is an important regulator of nucleation sites, and regulation of protein trafficking through might involve control over microtubule stability or distribution of tion in these contexts remains to be explored. This modulation in macrophages. How MARK4 modulates microtubule organiza-

evening in MTOC for efficient complex assembly and cleavage. Thus, upon receiving stimuli (polarizing cues) at the cell periphery, NLRP3 loading on the microtubule plus end track will allow its fast trafficking along microtubules for its correct delivery to microtubule minus end at MTOC (centrosome). On the basis of our data and previous knowledge, we propose that upon stimulation, on its trafficking route to MTOC, NLRP3 is first transported along the microtubule track to meet mitochondria, perhaps for its optimal energy loading, then further transported to the microtubule track minus end MTOC for optimal assembly and efficient protein cleavage (Supplementary Fig. 16). MARK4

MARKs and their invertebrate homologue Par-1 are conserved regulators of the organization of microtubule arrays, and they are important for the establishment of cell polarity and for fate determination in polarized structures like Drosophila oocytes and epithelia15,29,42. There is a network of cross-regulatory and feedback interactions between MARK (Par-1) protein, other polarity regulators and the cytoskeleton. Studies show that distinct microtubule-based transport mechanisms contribute to the establishment of PAR and its substrates asymmetries in different cell types30,43,44, and PAR also drives the proper organization of microtubules32,45. However, we did not know whether similar mechanisms were employed by MARK4 in the context of the innate immune response.

Here we demonstrate that inflammasome stimuli can act as polarizing cues to initiate dynamic NLRP3 and MARK4 transport in macrophages. How MARK4 modulates microtubule organization in these contexts remains to be explored. This modulation might involve control over microtubule stability or distribution of nucleation sites, and regulation of protein trafficking through MARK4 ability to interact with components of the cell’s apparatus. Microtubule acetylation is an important regulator of NLRP3 activation5. However, we did not detect any alteration of total or acetylated tubulin in MARK4 deficient cells, suggesting that MARK4 regulates NLRP3 activity through different mechanisms. Rather, we showed that MARK4 affected microtubule nucleation and the distribution of its binding partner NLRP3 on microtubule polarized minus end of MTOC, in agreement with the developmentally conserved role of MARK4. Binding of MARK4 to NLRP3 was required for NLRP3 transport to the mitochondria but also for delivering NLRP3 on MTOC, leading to the formation of a single inflammasome complex per cell and ensuring optimal activation of the inflammasome. Our study reveals a previously unappreciated mechanism through which a MARK protein can facilitate the formation of a complex structure involved in the activation of innate immunity. Recent data indicate that a centrosomal protein NEK7 is important in the regulation of NLRP3 activity7–9. Our results add more to this scenario and show that delivery of NLRP3 through a MARK4-regulated machinery to the correct position on MTOC (centrosome) is also very important in determining NLRP3 activation. Our results show that NLRP3 is very dynamic within the cell and is transported along microtubules. Why does NLRP3 need to be transported along this cytoskeleton? Inflammasome activation requires a few components to form one big complex, and also the protease activity to cleave the pro-form proteins and then deliver the final active output. Hence, inflammasome needs platforms like MTOC for efficient complex assembly and cleavage. Thus, upon receiving stimuli (polarizing cues) at the cell periphery, NLRP3 loading on the microtubule plus end track will allow its fast trafficking along microtubules for its correct delivery to microtubule minus end at MTOC (centrosome). On the basis of our data and previous knowledge, we propose that upon stimulation, on its trafficking route to MTOC, NLRP3 is first transported along the microtubule track to meet mitochondria, perhaps for its optimal energy loading, then further transported to the microtubule track minus end MTOC for optimal assembly and efficient protein cleavage (Supplementary Fig. 16). MARK4
affects the transport of NLRP3 to those destinations, rather than affecting the assembly of the big complex. In addition, we observe that once NLRP3 reaches the MTOC and assembles into a single speck structure, it is no longer localized on the mitochondria, which are now surrounding the MTOC, suggesting that localization of NLRP3 to the mitochondria is a transient state. Furthermore, it is still not clear how IL-1β is released on NLRP3 activation, and whether IL-1β release relies on microtubule-dependent transport and MARK4 function. Those hypotheses need to be further investigated in details. However, targeting MARK4/NLRP3 interaction or loss of MARK4 significantly affects NLRP3 inflammasome transport, positioning on MTOC, ASC oligomerization, and levels of caspase-1 and IL-1β in active forms (Figs 1 and 6; Supplementary Figs 13 and 14), strongly suggesting that interaction between MARK4 and NLRP3 is required for optimal NLRP3 function.

Taken together, our data unravel novel mechanistic roles of MARK4 in regulating NLRP3 inflammasome activation. Most current therapeutic strategies aimed at reducing NLRP3-mediated diseases involve blockade of the end-product IL-1β. Such strategies entail a number of potential undesirable effects, which are frequently associated with the suppression of a major cytokine involved in a wide range of NLRP3-dependent and -independent (patho) physiological processes. In this regard, our study clearly highlights an unconventional and more selective strategy for suppression of excessive NLRP3 inflammasome through the targeting of MARK4/NLRP3 interaction.

Methods

Mice. Mark4^−/− (ref. 13) and Nlrp3^−/− (ref. 5) mice were described. All mice were fully backcrossed to a C57BL/6 background. Dr Aubry Tardivel (University of Lausanne, Switzerland) provided bone marrow cells from Nlrp3^−/− mice, and Prof Clare Bryant (University of Cambridge, UK) and Prof Kate Fitzgerald (UMASS medical school, USA) provided Nlrp3^−/− mice. All studies were approved by Home Office, United Kingdom, and were performed under PPL 80/2426.

MSU-induced peritonitis model. Age (8 to 10 weeks) and sex-matched male Mark4^−/− mice and their littermate Mark4^+/+ wild-type controls were used for in vivo experiments. The littersmates were obtained by breeding Mark4^−/−/+ parents. Mouse fed with a chow diet was injected intravenously with 10 μg of anti-IL-1β antibody (AF-401-NA, R&D). After 30 min, mouse was injected intraperitoneally with 1 mg MSU in 0.3 ml sterile PBS. Six hours after MSU injection, animals were killed by CO2 asphyxiation and peritoneal exudates were collected by lavage and analysed.

Reagents. ATP, Ultrapure LPS, colchicine, nocardazole, MDP, Phorbol 12-myristate 13-acetate (PMA), and doxycycline were obtained from Sigma. Imject Alum was obtained from Thermo. Nigericin, flagellin, poly (dA:dT) and vinblastine were obtained from Enzo. iE-DAP was obtained from Invivogen. MSU crystals and cholesterol crystals were made as described46,47: cholesterol (Sigma) dissolved in 1,600 ml of boiling water containing 49 ml NaOH, and then PH was adjusted to 7.2, and crystals were formed by gradual cooling down. DOTAP (Roche), and Alum was obtained from Thermo. Nigericin, flagellin, poly (dA:dT) and vinblastine were obtained from Thermo. Ly6G (BD, 551461, 1 in 400 dilution), Ly6C (AbD SeroTec, mca771a647, 1 in 800 dilution), F4/80 (ebiosciences, 25-4801-82, 1 in 200 dilution), and Ly6C (AbD SeroTec, mca771a647, 1 in 400 dilution) were used for flow cytometry. See Supplementary Fig. 15d for gating strategy for peritoneal exudates.

Cell culture. Bone marrow cells were dissected from femur and tibia from 6-week old male mice. Bone marrow cells were differentiated into macrophages as previously described48 by using 25% conditional medium from L929 cells (ATCC) containing 25% FBS and levetiracetam and with microphage colony-stimulating factor (M-CSF) for 7 to 10 days. The differentiation of BMDM was confirmed by flow cytometry with markers CD11b (BIOLEGEND, 101217, 1 in 800 dilution), F4/80 (biosciences, 25-4801-82, 1 in 200 dilution), Ly6G (BD, 551461, 1 in 400 dilution), and Ly6C (AbD SeroTec, mca771a647, 1 in 400 dilution) were used for flow cytometry. See Supplementary Fig. 15d for gating strategy for peritoneal exudates.

Treatments. Inflammasome activation was induced by the following treatments as indicated: 5 mM of ATP for 30 min; 3 μM of nigericin for 2 h; 10 μM of nigericin for 1 h; 250 μg ml −1 of MSU for 3 h; 250 μg ml −1 of cholesterol crystals for 3 h; 250 μg ml −1 of Alum crystals for 3 h; 1 μg ml −1 of flagellin for 2 h; 2 μg ml −1 of poly (dA:dT) for 2 h; 10 μg ml −1 of MDP for 18 h; 10 μg ml −1 of iE-DAP for 18 h. Before inflammasome activation, BMDM cells were pretreated with the following reagents: 10 μM of colchicine for 1 h; 10 μM of nocardazole for 1 h; 10 μM of vinblastine for 1 h. BMDM were primed with LPS 100 ng ml −1 for 6 h before inflammasome activation.

Lentivirus transduction. Lentivus expression plasmids (Origene) were packaged and produced by transient transfection of packaging HEK293T cells (ATCC) for the inducer (manufacturer’s instruction (Origene). THP-1 cells or BMDM were transduced with packaged lentivirus following manufacturer’s instruction (Origene). Stably transduced THP-1 cells were selected by GFP or Cherry fluorescence using flow sorting. Tet-on system was used as described50 to induce Cherry-NLRP3 or GFP-MARK4 in THP-1 cells or BMDM by adding doxycycline (2 μg ml −1 ).

Transfection. On-target siRNAs were obtained from Dharmacon technologies (Thermo), and siRNA of non-targeting pool was used as a negative control. siRNA were transfected using TransIT TKO (Mirus Bio) as per manufacturer’s instructions. HEK293T cells were transfected with plasmids using TransIT/LI following manufacturer’s instruction, and the transfection efficiency was achieved more than 92%. One hour before inflammasome activation, cells were transfected with CagA peptide (GFPLKRHDGVDDLSKVG) and control peptide (data not shown) for 2 h; 10 μg ml −1 of MDP for 18 h; 10 μg ml −1 of iE-DAP for 18 h. Before inflammasome activation, BMDM cells were pretreated with the following reagents: 10 μM of colchicine for 1 h; 10 μM of nocardazole for 1 h; 10 μM of vinblastine for 1 h. BMDM were primed with LPS 100 ng ml −1 for 6 h before inflammasome activation.

Live cell labelling and imaging. HEK293T cells or THP-1 cells were grown on the eight-well chamber (Nunc). Cells were labelled with Mitotracker Red, Mitotracker Deep Red FM, TubulinTracker Green, and Hoechst 33342, DAPI were obtained from Invitrogen. CytoTox 96 non-radioactive cytotoxicity assay (Promega) was used to measure lactate dehydrogenase (LDH) as an indication of cell viability following manufacturer’s instruction.

Plasmids and molecular biology. Human NLRP3 cDNA clone was purchased from Applied Biological Materials. Full-length and truncated human NLRP3 (94–979; 1–220; 1–389; 1–574; 575–979) were subcloned into pCMV-3Tag-1. Point mutations (L141G R43Q V52Q L54Q) were created by site-directed mutagenesis. Human NLRP1, mouse NLR4, and human AIM2 cloned into pCMV-3Tag-1 (Flag tag) were obtained from Dr John MacMicking (University of Yale, USA). Human ASC subcloned into pCA7-Flag was obtained from Dr Takechi Iinohone and Dr Yusuke Yanagi (Kyushu University, Japan). Full-length NLRP3 was subcloned into pCMV-3Tag-1. Lentivirus packaging plasmids were purchased (Origene). Tet-O-FUW-EGFP (Addgene) was modified to subclone GFP-MARK4 or Cherry-NLRP3 into Tet-O-FUW backbone. FUW-M2rtTA (Addgene) was used to co-express the reverse tetracycline transactivator. NLRP3 (1-219 aa) was subcloned into pGEX-4T-3 vector to express GST fusion protein.

Antibodies. Antibodies against NLRP3 (Adipogen, Cryo2) (Sigma, HPA012878), IL-1β (R&D systems, AF-401-NA), caspase-1 (Santa Cruz, SC-154), MAP1 (Sigma, HM-1), NEK7 (Abcam, ab13354), MAP4 (BD, 611006). 2-tubulin (MBL, PM054), acetylated tubulin (Santa Cruz, SC-23950), γ-tubulin (Sigma, T5326), Tom20 (Santa Cruz, FL-145, SC-11451), ERK2 (Santa Cruz, C-14), HA tag (Santa Cruz, y-11), Flag tag (Sigma, F1804) were used for western blots. Antibodies against MARK4 (Cell Signaling, 4834) (Abcam, ab21427) (Thermo), and MARK4 (University of Dundee, UK), NLRP3 (Sigma, HPA012878; Abcam, ab4207), ASC (Enzo, ADI-905-173) (Santa Cruz, SC-33958) were used for in situ proximity-ligation assay. Antibodies against markers CD11b (BIOLEGEND, 101217, 1 in 800 dilution), F4/80 (biosciences, 25-4801-82, 1 in 200 dilution), Ly6G (BD, 551461, 1 in 400 dilution), and Ly6C (AbD SeroTec, mca771a647, 1 in 400 dilution) were used for flow cytometry. See Supplementary Fig. 15d for gating strategy for peritoneal exudates.

Analysis of NLRP3 motility. The intracellular translocation of fluorescent NLRP3 particles was analysed using Image processing program, ImageJ (NIH). The particles movements were tracked by generating time-space plot or kymograph.
First, the region of interest (ROI) in the cell was determined for each individual particle/fluorescent spot, and line ROI is drawn across the length of the movement that is manually created. Kymograph was generated that represents position of the fluorescent spot through the 100 frames of images. On kymograph, x axis represents the distance and y axis represents the time. The particle movement is seen as the change in position of high intensity spot from previous frames; the immobile particle appears as a single high intensity line parallel to y axis. Examples of kymographs illustrating unidirectional, bidirectional movements along the region of interest were presented. The run lengths and velocities were then calculated manually from the position of spots on kymographs. Run length was determined as a distance fluorescent particle travelled before stalling or reversing its direction of movement. Velocity was calculated as displacement per interval time. N = 111 (from 3 cells) for Control shRNA and N = 136 (from 4 cells) particles tracks for MARK4 shRNA were analysed.

**In situ proximity-ligation assay.** In situ proximity ligation assay (in situ PLA) is suitable for quantitative studies of protein expressions, and to characterize modifications and interactions of proteins. The cells were cultured on eight-well chamber slide (Nunc). PLA assay was performed according to manufacturer’s instructions (Olink). Living cells treated with marker Red CMXRsos were fixed by 4% PFA, and then subject to PLA assay. Nucleus was revealed in blue in the images. PLA signal (indicated by symbol ‘X’ per cytoplasm of a cell) was acquired using Duolink analysis software (Olink). Mitochondria overlapped with PLA signal was analysed as overlap coefficient by using Zen software.

**Coimmunoprecipitation assay.** Cell lysates from HEK293T cells were collected and lysed in the triton lysis buffer: 10 mM Tris-HCl pH 8.0, 2.5 mM MgCl₂, 5 mM EGTA pH 8.0, 0.5% Triton X-100 (w/v), 1 mM Na₃VO₄, 50 mM NaF and 1 tablet of protease inhibitor cocktail (Roche) per 10 ml of buffer. Anti-Flag M2 magnetic beads (Sigma) were used to isolate co-immunoprecipitated complex with Flag-tagged proteins, and Anti-HA matrix (Roche) were used to isolate co-immunoprecipitated complex with HA-tagged proteins. Beads and matrix were washed following manufacturer’s instruction.

**GST pull-down assay.** The GST-tagged NLRP3 (1-219aa) was induced and expressed as described. Purified GST-tagged NLRP3 (1-219 aa) was immobilized on the glutathione sepharose 4B beads (GE healthcare). Purified full-length recombinant MARK4 protein was obtained from MRC-PUC (the University of Dundee, UK), and applied to those beads. Washing steps were followed as described. Samples were then subjected to western blot analysis.

**ASC oligomerization assay.** Cells were lysed with TBS-triton buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% Triton X-100) complemented with EDTA-free protease inhibitor (Roche). The lysates were centrifuged at 6,000 g for 15 min at 4 °C. The pellets were used as triton-insoluble fraction, and the supernatants were used as triton-soluble fraction. The triton-insoluble pellets were washed twice with TBS buffer (50 mM Tris-HCL, pH 7.4, 150 mM NaCl). The pellets were then resuspended in 300 µl TBS buffer. The resuspended pellets underwent crosslinkage for 30 min at 37 °C with 2 mM disuccinimidyl dithiocarbamate (Pierce), and the samples were centrifuged and dissolved in LDS sample buffer for western blot.

**Western blot.** Supernatant of cells stimulated with inflammasome activator was collected in serum-free media. TCA protein precipitation was performed on those supernatant to detect cleaved IL-1β and caspase-1. Western samples were separated on precast NuPAGE Novex 4-12% Bis-Tris gels (Invitrogen), and proteins were transferred onto PVDF Immobilon-FL membrane (Millipore). After antibody using precast NuPAGE Novex 4–12% Bis-Tris gels (Invitrogen), and proteins were labeled with markers CD11b, Ly6G, and Ly6C. Stained cells were subject to staining with markers CD11b, Ly6G, and Ly6C. Stained cells were subject to Fortessa Cell Analyser (BD, USA). Ly6G⁺Ly6C⁺ cells from CD11b positive cells were counted as neutrophil. Data were analysed by Flowjo.

**Neutrophil migration assay.** Mouse neutrophils were isolated from blood using millenyi biotech kit (Millenyi). Isolated neutrophil were then subject to transwell migration assay, and CXCL12 was as attractant. The incubation was performed in 37 °C cell culture incubator for 4 h. Migrated cells were then collected and counted.

**Phagocytosis assay.** Cells were co-incubated with MSU crystals for 4 h at 37 °C cell culture incubator. Cells were then thoroughly washed and stained with Cholera Toxin Subunit B (Invitrogen). Phagocytosed MSU images were taken by reflected confocal microscopy. Fluorescence intensity of phagocytosed MSU was analysed by reflection signals per cell. Analysis was performed using ImageJ. Vybrant phagocytosis assay kit (Invitrogen) was also used following manufacturer’s instructions.

**Statistics.** Statistical analysis was performed with Prism (Graphpad). All data were expressed as Mean ± s.e.m. Comparisons of the two different groups were analysed by unpaired t test. P<0.05 (*), P<0.01 (**), P<0.001 (***), or P<0.0001 (****) was considered statistically significant.

**Data availability.** The data that support the findings of this study are available from the corresponding author upon reasonable request.

**References.**

1. Strowig, T., Henao-Mejia, J., Elinav, E. & Flavell, R. Inflammasomes in health and disease. Nature 481, 278–286 (2012).
2. Duewell, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357–1361 (2010).
3. Heneka, M. T. et al. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PSE1 mice. Nature 493, 674–678 (2013).
4. Hancock, W. O. Readirectional cargo transport: moving beyond tug of war. Nat. Rev. Mol. Biol. 15, 615–628 (2014).
5. Martinon, F., Petrelli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237–241 (2006).
6. Misawa, T. et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat. Immunol. 14, 454–460 (2013).
7. He, Y., Zeng, M. Y., Yang, D., Motro, B. & Nunez, G. NLRP3 is an essential mediator of NLRP3 activation downstream of potassium efflux. Nature 530, 354–357 (2016).
8. Shi, H. et al. NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component. Nat. Immunol. 17, 250–258 (2016).
9. Schmid-Burgk, J. L. et al. A genome-wide crispr (clustered regularly interspaced short palindromic repeats) screen identifies NEK7 as an essential component of NLRP3 inflammasome activation. J. Biol. Chem. 291, 103–109 (2016).
10. Trinczek, B., Brajenovic, M., Ehnert, A. & Drewes, G. MARK4 is a novel microtubule-associated proteins/microtubule affinity-regulating kinase that binds to the cellular microtubule network and to centrosomes. J. Biol. Chem. 279, 5915–5923 (2004).
11. Kuhns, S. et al. The microtubule affinity regulating kinase MARK4 promotes axoneme extension during early ciliogenesis. J. Cell Biol. 200, 505–522 (2013).
12. Li, L. & Guan, K. L. Microtubule-associated protein/microtubule affinity-regulating kinase 4 (MARK4) is a negative regulator of the mammalian target of rapamycin complex 1 (mTORC1). J. Biol. Chem. 288, 703–708 (2013).
13. Sun, C. et al. Inactivation of MARK4, an AMP-activated protein kinase (AMPK)-related kinase, leads to insulin hypersensitivity and resistance to diet-induced obesity. J. Biol. Chem. 287, 38305–38315 (2012).
14. Rivina, D. et al. Microtubule-associated protein/microtubule affinity-regulating kinase 4 (MARK4) plays a role in cell cycle progression and cytoskeletal dynamics. Eur. J. Cell Biol. 93, 355–365 (2014).
15. Saadat, I. et al. Helicobacter pylori CagA targets PAR1/MARK kinase to disrupt epithelial cell polarity. Nature 447, 330–333 (2007).
16. Zaalur, N. et al. Proteasome failure promotes positioning of lysosomes around the aggresome via local block of microtubule-dependent transport. Mol. Cell Biol. 34, 1336–1348 (2014).
17. Schneider, A. et al. Identification of regulated genes during permanent focal cerebral ischaemia: characterization of the protein kinase 95β/MARK1/ MARK4. J. Neurochem. 88, 1114–1126 (2004).
18. Gu, G. J. et al. Role of individual MARK isoforms in phosphorylation of tau at Ser(2)/Ser(2) in Alzheimer’s disease. Neuron 30, 458–469 (2013).
19. Vandannagars, B. et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17, 179–188 (2011).
20. Soderberg, O. et al. Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay. Methods 45, 227–232 (2008).

21. Wemreck, I. et al. Proximity ligation assays: recent addition to the proteomics toolbox. Expert Rev. Proteomics 7, 401–409 (2010).

22. Shenyov, A. R. et al. GBP5 promotes NLRP3 inflammasome assembly and immunity in mammals. Science 336, 481–485 (2012).

23. Latz, E., Xiao, T. S. & Stutz, A. Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 13, 397–411 (2013).

24. Zhou, R., Yazdi, A. S., Menu, P. & Tschopp, J. A role for mitochondria in inflammasome activation. Cell 153, 348–361 (2013).

25. Bae, J. Y. & Park, H. H. Crystallization and preliminary X-ray crystallographic studies of the PYD domain of human NALP3. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 67, 1421–1424 (2011).

26. Bae, J. Y. & Park, H. H. Crystal structure of NALP3 protein pyrin domain (PYD) and its implications in inflammasome assembly. J. Biol. Chem. 286, 39328–39336 (2011).

27. Subramanian, N., Natarajan, K., Clatworthy, M. R., Wang, Z. & Germain, R. N. The adaptor MAVS promotes NLRP3 mitochondrial localization and inflammasome activation. Cell 153, 348–361 (2013).

28. Zhou, R., Yazdi, A. S., Menu, P. & Tschopp, J. A role for mitochondria in NLRP3 inflammasome activation. Nature 469, 221–225 (2011).

29. Tompanak, P. et al. A Drosophila melanogaster homologue of Caenorhabditis elegans lar-1 acts at an early step in embryonic-axis formation. Nat. Cell Biol. 2, 458–460 (2000).

30. Mendelkow, E. M., Thies, E., Trinczek, B., Biernat, J. & Mendelkow, E. MARK/PAR1 kinase is a regulator of microtubule-dependent transport in axons. J. Cell Biol. 167, 99–110 (2004).

31. Patel, P. C., Fisher, K. H., Yang, E. C., Deane, C. M. & Harrison, R. E. Proteomic analysis of microtubule-associated proteins during macrophage activation. Mol. Cell Proteomics 8, 2500–2514 (2009).

32. Jenardhanan, P., Mannu, J. & Mathur, P. P. The structural analysis of MARK4 and MARK6: a computational approach to obstruct the role of MARK4 in prostate cancer progression. Mol. Biol. Cell. 10, 1845–1868 (2014).

33. Gammon, K. Inflammation: a complex problem. Nat. Immunol. 13, 1384–1390 (2012).

34. Bae, J. Y. & Park, H. H. Crystal structure of NALP3 protein pyrin domain (PYD) and its implications in inflammasome assembly. J. Biol. Chem. 286, 39328–39336 (2011).

35. Bae, J. Y. & Park, H. H. Crystallization and preliminary X-ray crystallographic studies of the PYD domain of human NALP3. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 67, 1421–1424 (2011).

36. Bae, J. Y. & Park, H. H. Crystal structure of NALP3 protein pyrin domain (PYD) and its implications in inflammasome assembly. J. Biol. Chem. 286, 39328–39336 (2011).

37. Yu, W. Direct conversion of fibroblasts to functional neurons by directional reprogramming. Nature 518, 49–55 (2015).

38. So, A. Developments in the scientific and clinical understanding of gout. Hum. Mol. Genet. 14, 3483–3489 (2005).

39. Kim, J. Y. et al. Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay. Methods 45, 227–232 (2008).

40. Cox, D. N., Lu, B., Sun, T. Q., Williams, I. T. & Jan, Y. N. Drosophila par-1 is required for oocyte differentiation and microtubule organization. Curr. Biol. 11, 75–87 (2001).

41. Metegi, F. et al. Microtubules induce self-organization of polarized PAR domains in Caenorhabditis elegans zygotes. Nat. Cell Biol. 13, 1361–1367 (2011).

42. Riechmann, V., Gutierrez, G. J., Filaro, P., Nebreda, A. R. & Ephrussi, A. Par-1 regulates stability of the posterior determinant Oskar by phosphorylation. Nat. Cell Biol. 4, 337–342 (2002).

43. Parton, R. M. et al. A PAR-1-dependent orientation gradient of dynamic microtubules directs posterior cargo transport in the Drosophila oocyte. J. Cell Biol. 194, 121–135 (2011).

44. Rajamaki, K. et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS ONE 5, e11765 (2010).

45. Murakami, Y. et al. Induction of triggering receptor expressed on myeloid cells 1 in murine resident peritoneal macrophages by monosodium urate monohydrate crystals. Arthritis Rheum. 54, 455–462 (2006).

46. Guarda, G. et al. T cells dampen innate immune responses through inhibition of NLRP1 and NLRP3 inflammasomes. Nature 460, 269–273 (2009).

47. Vierbuchen, T. et al. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 463, 1035–1041 (2010).

48. Einarson, M. B., Pugacheva, E. N. & Orlinsk, J. R. GST pull-down. CSH Protoc. 2007 pdb prot4757 (2007).

Acknowledgements We thank people who have provided materials and reagents (stated in the Methods section), Simon Bullock for live imaging, Yang Liu for suggestions on structure analysis, Gemma Basatemur and Jill Reckless for providing THP-1 cells, Romina Macco from Bruker for using Opterra, Yuning Lu for assistance on neutrophil migration assay, Marc Clement for comments on the manuscript. We thank BRC cell phenotyping hub for assisting on flow sorting and flow cytometry. We thank core biochemical assay lab for performing MSD assay. The work was supported by NNSFC grant (81370620 to G.M.), BHF grant (CH/10/001/27642 to Z.M.), ERC grant (289184 to Z.M.), and BHF fellowship grant (FS/14/28/30713 to X.L.).

Author contributions X.L. conceived ideas, supervised project, designed and performed experiments, analysed and interpreted the data, and wrote the manuscript. S.T. performed the following experiments and analysed the data: genotyping, flow cytometry, cell line establishment, immunocytochemistry, imaging, western blot experiments described in the Figures and Supplementary Figures. SDM performed cloning experiment described in Fig. 3. M.A.-N. performed image analysis described in Supplementary Fig. 9. A.E. and L.K. performed mouse i.p. and i.v. infections described in Fig. 7. L.M. performed part of genotyping, J.R.J. assisted in live imaging. Y.S. created and provided MARK4 KO mouse colony. G.M. oversaw a portion of the work described in Fig. 3. Z.M. oversaw the project.

Additional information Supplementary Information accompanies this paper at http://www.nature.com/ncomms

Competing interests: The authors declare no competing financial interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

How to cite this article: Li, X et al. MARK4 regulates NLRP3 positioning and inflammasome activation through a microtubule-dependent mechanism. Nat. Commun. 8, 15986 doi: 10.1038/ncomms15986 (2017).

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2017